Results 1 to 10 of about 16,128 (142)

Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2. [PDF]

Mol Oncol
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Chatterjee J, Marin A, Yalala S, Itkonen HM.   +3 more
europepmc   +2 more sources

Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer. [PDF]

Adv Sci (Weinh)
The schematic diagram depicts a compartmentalized anti‐ferroptotic defense mechanism mediated by GSTA4. GSTA4 is upregulated and localizes to the cytoplasm in ENZR cells, where it detoxifies 4‐HNE via a non‐canonical GSH‐dependent pathway. Under oxidative stress, GSTA4 translocates to mitochondria, interacts with PGAM5, and blocks Drp1 Ser637 ...
Luo Y, Zhuang W, Li Z, Lai Y, Ou Y, Li D, Huang S, Luo T, Hu J, Chen B, Fu J, Zhuo T, Jiang H, Lu Y, Huang H, Xu K, Peng S, Yuan Q.   +17 more
europepmc   +2 more sources

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer. [PDF]

Prostate
ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Fujimoto S, Morita T, Yamamoto Y, Inamoto T, Tamura K, Yoshikawa Y, Maenosono R, Takeuchi A, Takahara K, Sugiyama S, Komura K, Yanagisawa T, Fukuokaya W, Kimura T, Fujita K.   +14 more
europepmc   +2 more sources

Histone lactylation modification promotes docetaxel resistance and tumor progression through CNN1-Mediated autophagy and cell cycle arrest in Castration-resistant prostate cancer [PDF]

Cell Death Discovery
Castration-resistant prostate cancer (CRPC) constitutes an advanced stage of prostate cancer (PCa) that emerges following conventional androgen deprivation therapy (ADT).
Ruijie Mao, Xu Chen, Xing Fu, Dingyuan Yang, Wenqiang Chen, Jun Li   +5 more
doaj   +2 more sources

Ablative radiotherapy in castration-resistant prostate cancer. [PDF]

BJU Int
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Hölscher T, Lohaus F, Koi L, Kotzerke J, Hoberück S, Thomas C, Borkowetz A, Löck S, Krause M, Troost EGC.   +9 more
europepmc   +2 more sources

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation

Frontiers in Oncology, 2022
The development of a neuroendocrine phenotype as a mechanism of resistance to hormonal treatment is observed in up to 20% of advanced prostate cancer patients.
Marco Bergamini, Alberto Dalla Volta, Irene Caramella, Luisa Bercich, Simona Fisogni, Mattia Bertoli, Francesca Valcamonico, Salvatore Grisanti, Pietro Luigi Poliani, Francesco Bertagna, Alfredo Berruti   +10 more
doaj   +1 more source

MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer

OncoImmunology, 2022
The oncogenic MUC1-C protein drives dedifferentiation of castrate resistant prostate cancer (CRPC) cells in association with chromatin remodeling. The present work demonstrates that MUC1-C is necessary for expression of IFNGR1 and activation of the type ...
Masayuki Hagiwara, Atsushi Fushimi, Atrayee Bhattacharya, Nami Yamashita, Yoshihiro Morimoto, Mototsugu Oya, Henry G. Withers, Qiang Hu, Tao Liu, Song Liu, Kwok K. Wong, Mark D. Long, Donald Kufe   +12 more
doaj   +1 more source

Studies on Changes of Physicochemical Properties in Shuidouchi before and after Fermentation and the Inhibitory Effect of Its Extracts on Prostate Cancer Cells

Shipin gongye ke-ji, 2022
Objective: To study the changes of physicochemical properties in Shuidouchi before and after fermentation, and to preliminarily explore the inhibitory effect of its extracts on castration-resistant prostate cancer cells (CRPC).
Lan YOU, Ke DONG, Ruocheng LUO, Xun HE, Shuhan LUO, Jiayi CHEN, Xiaofang PEI   +6 more
doaj   +1 more source

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report

Case Reports in Oncology, 2020
DNA repair mutations (BRCA1 and BRCA2) are found in metastatic castration-resistant prostate cancer (CRPC) patients. Here, we report a case of a 71-year-old male patient with metastatic CRPC along with BRCA2 and PTEN mutations.
Pramod Kumar Julka, Amit Verma, Kush Gupta   +2 more
doaj   +1 more source

Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer

Cancer Biology & Medicine, 2022
Objective: To explore the genetic changes in the progression of castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) and the reason why these cancers resist existing therapies.
Qiong Wang, Zean Li, Jin Yang, Shirong Peng, Qianghua Zhou, Kai Yao, Wenli Cai, Zhongqiu Xie, Fujun Qin, Hui Li, Xu Chen, Kaiwen Li, Hai Huang   +12 more
doaj   +1 more source